Sven Björkman

Summary

Affiliation: Apoteket AB
Country: Sweden

Publications

  1. ncbi request reprint Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis
    S Bjorkman
    Hospital Pharmacy, Malmo University Hospital, Malmo, Sweden
    Haemophilia 7:133-9. 2001
  2. pmc Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs
    Sven Björkman
    Hospital Pharmacy, Malmo University Hospital, Malmö and Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
    Br J Clin Pharmacol 59:691-704. 2005
  3. ncbi request reprint Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective
    S Bjorkman
    Hospital Pharmacy, Malmo University Hospital, Sweden
    Haemophilia 9:101-8; discussion 109-10. 2003
  4. ncbi request reprint Prediction of the volume of distribution of a drug: which tissue-plasma partition coefficients are needed?
    Sven Björkman
    Hospital Pharmacy, Malmo University Hospital, Sweden
    J Pharm Pharmacol 54:1237-45. 2002
  5. ncbi request reprint A comment on the application of drug tissue-plasma partition coefficients K(p) in eliminating organs to calculation of volume of distribution at steady state
    Sven Björkman
    Hospital Pharmacy, Malmo University Hospital, Malmo, Sweden
    J Pharmacokinet Pharmacodyn 32:655-8. 2005
  6. ncbi request reprint Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?
    Sven Björkman
    Hospital Pharmacy, Malmo University Hospital, Malmo, Sweden
    Clin Pharmacokinet 45:1-11. 2006
  7. ncbi request reprint Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model
    S Bjorkman
    Hospital Pharmacy, Malmo University Hospital, S 205 02 Malmo, Sweden
    J Pharm Sci 90:1226-41. 2001
  8. ncbi request reprint Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia
    S Bjorkman
    Hospital Pharmacy and Department for Coagulation Disorders, Malmo University Hospital, Sweden
    Clin Pharmacokinet 40:815-32. 2001
  9. ncbi request reprint Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models
    Sven Björkman
    Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala and Hospital Pharmacy, Malmo University Hospital, Malmo, Sweden
    J Pharmacokinet Pharmacodyn 30:285-307. 2003
  10. ncbi request reprint Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors
    Tord Juhlin
    Department of Cardiology, Malmo University Hospital, Malmo, Sweden
    Eur J Heart Fail 6:909-16. 2004

Detail Information

Publications21

  1. ncbi request reprint Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis
    S Bjorkman
    Hospital Pharmacy, Malmo University Hospital, Malmo, Sweden
    Haemophilia 7:133-9. 2001
    ..During prophylaxis a 1-U dL(-1) trough level can normally be maintained by dosing every 2-3 days, the former schedule resulting in, on average, a 45% lower consumption of rFIX...
  2. pmc Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs
    Sven Björkman
    Hospital Pharmacy, Malmo University Hospital, Malmö and Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
    Br J Clin Pharmacol 59:691-704. 2005
    ..To create a general physiologically based pharmacokinetic (PBPK) model for drug disposition in infants and children, covering the age range from birth to adulthood, and to evaluate it with theophylline and midazolam as model drugs...
  3. ncbi request reprint Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective
    S Bjorkman
    Hospital Pharmacy, Malmo University Hospital, Sweden
    Haemophilia 9:101-8; discussion 109-10. 2003
    ..Chiefly for economic reasons, the minimum effective dosage of coagulation factor should be determined and used in every patient. The dose requirement should also be re-evaluated at appropriate times...
  4. ncbi request reprint Prediction of the volume of distribution of a drug: which tissue-plasma partition coefficients are needed?
    Sven Björkman
    Hospital Pharmacy, Malmo University Hospital, Sweden
    J Pharm Pharmacol 54:1237-45. 2002
    ..The muscle Kp can be used to represent all lean tissues, including the residual "carcass", with the exception that fat Kp can be used for distribution of basic drugs to lungs...
  5. ncbi request reprint A comment on the application of drug tissue-plasma partition coefficients K(p) in eliminating organs to calculation of volume of distribution at steady state
    Sven Björkman
    Hospital Pharmacy, Malmo University Hospital, Malmo, Sweden
    J Pharmacokinet Pharmacodyn 32:655-8. 2005
  6. ncbi request reprint Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?
    Sven Björkman
    Hospital Pharmacy, Malmo University Hospital, Malmo, Sweden
    Clin Pharmacokinet 45:1-11. 2006
    ..Neither of the methods can be used as a substitute for actual clinical studies...
  7. ncbi request reprint Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model
    S Bjorkman
    Hospital Pharmacy, Malmo University Hospital, S 205 02 Malmo, Sweden
    J Pharm Sci 90:1226-41. 2001
    ..Interindividual variation in the disposition of midazolam could thus in part be related to the physiological characteristics of the patients and the f(u) of the drug in their plasma...
  8. ncbi request reprint Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia
    S Bjorkman
    Hospital Pharmacy and Department for Coagulation Disorders, Malmo University Hospital, Sweden
    Clin Pharmacokinet 40:815-32. 2001
    ..In conclusion, therapeutic monitoring of coagulation factor levels and the use of clinical pharmacokinetics to aid therapy are well established in the treatment of patients with haemophilia...
  9. ncbi request reprint Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models
    Sven Björkman
    Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala and Hospital Pharmacy, Malmo University Hospital, Malmo, Sweden
    J Pharmacokinet Pharmacodyn 30:285-307. 2003
    ..Organs of particular pharmacological or toxicological interest should of course be investigated separately as needed. This study also suggests and applies a simple method for statistical evaluation of the predictions of PBPK models...
  10. ncbi request reprint Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors
    Tord Juhlin
    Department of Cardiology, Malmo University Hospital, Malmo, Sweden
    Eur J Heart Fail 6:909-16. 2004
    ....
  11. ncbi request reprint In-vitro release of bupivacaine from injectable lipid formulations investigated by a single drop technique--relation to duration of action in-vivo
    Lars Söderberg
    Hospital Pharmacy, Malmo University Hospital, Sweden
    J Pharm Pharmacol 54:747-55. 2002
    ..The apparatus is, however, as yet a prototype. Rigorous evaluation of performance should be carried out on devices built to specific standards according to their intended application...
  12. ncbi request reprint Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight
    Sven Björkman
    Department of Pharmaceutical Biosciences, Uppsala University, Sweden
    Blood 119:612-8. 2012
    ..The obtained findings can be used as a basis for PK-based dose tailoring of FVIII in clinical practice, in all age groups, with minimal blood sampling...
  13. ncbi request reprint Local anesthetics in lipid-depot formulations--neurotoxicity in relation to duration of effect in a rat model
    Henrik Dyhre
    Department of Anaesthesia and Intensive Care Lund University, Malmo University Hospital, Malmo, Sweden
    Reg Anesth Pain Med 31:401-8. 2006
    ..The aim of this study was to investigate the possible local neurotoxicity of a number of lipid-depot formulations of local anesthetics in relation to their duration of action in sciatic-nerve block...
  14. ncbi request reprint Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A
    Sven Björkman
    Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE 751 24, Uppsala, Sweden
    Eur J Clin Pharmacol 65:989-98. 2009
    ....
  15. ncbi request reprint The "inverted cup" -- a novel in vitro release technique for drugs in lipid formulations
    Lars Söderberg
    Hospital Pharmacy, Malmo University Hospital, Malmo, Sweden Department of Food Technology, Lund University, Lund, Sweden
    J Control Release 113:80-8. 2006
    ..In conclusion, the "inverted cup" technique should potentially be applicable to a wide range of lipid formulations of drugs, both for physico-chemical characterisation and for obtaining in vitro -- in vivo correlations...
  16. ncbi request reprint Cyclooxygenase inhibition causes marked impairment of renal function in elderly subjects treated with diuretics and ACE-inhibitors
    Tord Juhlin
    Department of Cardiology, Malmo University Hospital, Malmo, Sweden
    Eur J Heart Fail 7:1049-56. 2005
    ..The long-term beneficial effects of ACE-inhibitors in these patients can be counteracted by cyclooxygenase-inhibitors...
  17. ncbi request reprint Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans
    Marie Nicklasson
    Hospital Pharmacy, Malmo University Hospital, Malmo, Sweden
    Chirality 14:643-52. 2002
    ..019-0.037 after oral administration of 600 mg. The biotransformation of pentoxifylline to M1 was thus highly stereoselective in favor of the (S)-enantiomer both in vitro and in vivo...
  18. ncbi request reprint Ultralong peripheral nerve block by lidocaine:prilocaine 1:1 mixture in a lipid depot formulation: comparison of in vitro, in vivo, and effect kinetics
    Lars Söderberg
    Hospital Pharmacy, Malmo University Hospital, Sweden
    Anesthesiology 104:110-21. 2006
    ..The aim of this study was to develop stable and easily injectable lipid depot preparations of local anesthetics in which the drug concentration can be varied according to desired duration of action...
  19. ncbi request reprint Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis
    Sven Björkman
    Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
    Eur J Clin Pharmacol 68:969-77. 2012
    ....
  20. ncbi request reprint Pharmacokinetics and antidiuretic effect of high-dose desmopressin in patients with chronic renal failure
    Hana Ruzicka
    Department of Nephrology and Transplantation, Malmo University Hospital, Malmo, Sweden
    Pharmacol Toxicol 92:137-42. 2003
    ..The single haemostatic dose of desmopressin given to patients with severe renal failure did not cause fluid overload or changes in serum electrolytes...
  21. ncbi request reprint Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsin
    Eeva Piitulainen
    Department of Respiratory Medicine, Malmo University Hospital, Lund University, 20502, Malmo, Sweden
    Eur J Clin Pharmacol 59:151-6. 2003
    ..The objective of this investigation was to study whether tailored pharmacokinetic dosing of human AAT allows self-administration and reduces the total annual dose and cost of intravenous augmentation therapy...